SubjectWell Expands Executive Leadership to Realize Growth Strategy
AUSTIN, TX, April 6, 2023 – SubjectWell, the largest engagement platform for matching patients with chronic health conditions to new care options, announced that clinical industry veteran Fred Martin has joined SubjectWell as CEO. After an extensive year-long search for a proven leader with the right combination of experience accelerating technical solutions and building investor […]
Compensation norms create inequity in clinical trials
Exploring how compensation practices in clinical trials contribute to inequities and hinder diverse patient participation
US Tech Startup SubjectWell Secures $35 Million in Investment, Focuses Growth in South African Operations
AUSTIN, TX, November 10, 2022 – SubjectWell, the largest engagement platform for matching patients with chronic health conditions to new care options in clinical trials, recently announced a R630 Million ($35 million USD) Series B funding round led by Asset Management Ventures. This new investment will accelerate the growth of SubjectWell’s existing clinical trial patient […]
How race and secondary conditions influence diabetes clinical trial interest
The impact of secondary conditions on clinical trial interest.
Funding Roundup: SubjectWell, Alto Neuroscience, ConnexPay, SUN METALON, Wispr, Paragraph, Merge, InfinyOn, Shadowbox, Electronic Caregiver, And Grafbase.
Clinical trial recruitment platform SubjectWell scores $35M
SubjectWell raises $35M to expand access to clinical trials for cancer and other diseases
Read full article from Austin Inno
Across multiple demographics, accommodations boost patient interest in clinical trial participation and barriers lower interest
Strategies to boost diversity in clinical trials.
Spanish-Speaking Patients Show Strong Interest in Trial Participation in the U.S.
For a clinical trial to be successful, patients need to be the top priority. However, language barriers faced during the clinical trial process can often result in lower participation rates of non-English speakers, an unsatisfactory patient experience and, ultimately, imprecise data. In the US, the leading country in clinical trial participation each year, language barriers are […]
